News

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.
Every bladder cancer journey is different, and no single treatment or diagnostic path fits everyone. According to patients who have experienced bladder cancer, the best care for you will depend on ...
Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Beat bladder cancer with early detection! Expert insights reveal how a multidisciplinary approach can improve treatment outcomes in India. Learn more about effective care.
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...
The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...
Bladder cancer may be scary but it will help to know that depending on the stage of cancer treatment will help control or ...
Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...
Joseph Jacob, MD, discusses the promising impact of TAR-200.
Multidisciplinary care, a collaborative approach where various healthcare disciplines come together, is essential for treating those with prostate cancer.
UK MHRA approves Serum Life Science Europe’s Anktiva to treat adult patients with non-muscle invasive bladder cancer: United Kingdom Monday, July 7, 2025, 12:00 Hrs [IST] The UK ...